{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:18:55Z","timestamp":1785338335220,"version":"3.55.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Recent studies have demonstrated mortality benefits from corticosteroid use in COVID-19 patients requiring respiratory support. However, clinical practice may warrant the use of corticosteroids outside the context of a clinical trial. Such data are rarely, if ever, reported. We explored the use of corticosteroids for adult respiratory distress syndrome (ARDS) indications in patients with non-COVID ARDS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively studied patients with moderate-to-severe ARDS, admitted to our intensive care unit (ICU) between January 2018 and March 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Of the 91 patients with ARDS identified, 80% were treated with a corticosteroid during their ICU admission. Of these, 73 (82%) had corticosteroids administered for reasons other than ARDS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Corticosteroid use for non-ARDS indications is commonplace in ARDS patients in our ICU. The use of corticosteroids outside a randomisation process in randomised clinical trials may be more common than appreciated and needs to be routinely reported.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijpp\/riab053","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:42:45Z","timestamp":1628538165000},"page":"642-644","source":"Crossref","is-referenced-by-count":2,"title":["Corticosteroids in adult respiratory distress syndrome \u2013 an inconvenient truth?"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9650-3718","authenticated-orcid":false,"given":"Rob","family":"Shulman","sequence":"first","affiliation":[{"name":"Pharmacy Department, CMORE, University College Hospital NHS Foundation Trust, London, UK"},{"name":"Critical Care Department, University College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Montanari","sequence":"additional","affiliation":[{"name":"Pharmacy Department, CMORE, University College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Pharmacy Department, CMORE, University College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Longobardo","sequence":"additional","affiliation":[{"name":"Critical Care Department, University College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Benhalm","sequence":"additional","affiliation":[{"name":"Critical Care Department, University College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Polhill","sequence":"additional","affiliation":[{"name":"Critical Care Department, University College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[{"name":"Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Bellingan","sequence":"additional","affiliation":[{"name":"Critical Care Department, University College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishkantha","family":"Arulkumaran","sequence":"additional","affiliation":[{"name":"Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"2021120509111699700_CIT0001","volume-title":"Acute Respiratory Distress Syndrome","author":"Diamond","year":"2021"},{"key":"2021120509111699700_CIT0002","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume-title":"JAMA","author":"Sterne","year":"2020"},{"key":"2021120509111699700_CIT0003","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/aas.13795","article-title":"Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: protocol and statistical analysis plan","volume":"65","author":"Munch","year":"2021","journal-title":"Acta Anaesthesiol Scand"},{"key":"2021120509111699700_CIT0004","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2021120509111699700_CIT0005","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin Definition","volume":"307","author":"Ranieri","year":"2012","journal-title":"JAMA"},{"key":"2021120509111699700_CIT0006","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2021120509111699700_CIT0007","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1469-0691.2009.02752.x","article-title":"The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis","volume":"15","author":"Minneci","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2021120509111699700_CIT0008","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1378\/chest.06-2100","article-title":"Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial","volume":"131","author":"Meduri","year":"2007","journal-title":"Chest"},{"key":"2021120509111699700_CIT0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.280.2.159","article-title":"Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial","volume":"280","author":"Meduri","year":"1998","journal-title":"JAMA"},{"key":"2021120509111699700_CIT0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejcdt.2013.02.013","article-title":"Effects of methyl prednisolone in early ARDS","volume":"62","author":"Abdelsalam Rezk","year":"2013","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"2021120509111699700_CIT0011","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial","author":"Dequin","year":"2020","journal-title":"JAMA"},{"key":"2021120509111699700_CIT0012","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"2021120509111699700_CIT0013","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"key":"2021120509111699700_CIT0014","article-title":"Dexamethasone in hospitalized patients with Covid-19","author":"Horby","year":"2020","journal-title":"N Engl J Med"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/29\/6\/642\/41505931\/riab053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/29\/6\/642\/41505931\/riab053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T09:12:26Z","timestamp":1638695546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/29\/6\/642\/6362008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,9,1]]},"published-print":{"date-parts":[[2021,12,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riab053","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,9,1]]}}}